CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas By Ogkologos - July 16, 2026 122 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... January 16, 2021 Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal September 24, 2020 ΣΑΡΚΩΜΑ February 7, 2019 Treatment Strategy for ecDNA-Driven Tumors Shows Potential December 5, 2024 Load more HOT NEWS Two Women With Terminal Breast Cancer Started A Podcast That’s Unflinchingly... Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with... Creating a shared vision to detect cancer earlier ‘Normal’ cells and ‘cancer’s surprising circular DNA’: Inside Cancer Grand Challenges...
